Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Jared L. Crandon"'
Autor:
Jared L. Crandon, David P. Nicolau
Publikováno v:
Pathogens, Vol 4, Iss 3, Pp 620-625 (2015)
We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum β-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-su
Externí odkaz:
https://doaj.org/article/dd073fbf7cb2459892b2747115b7ae45
Publikováno v:
Heliyon, Vol 2, Iss 6 (2016)
Introduction: We aimed to describe the in vivo efficacy of meropenem, in addition to cefepime and levofloxacin as comparators against VIM-producing Pseudomonas aeruginosa and compare the findings to our previous observations with Enterobacteriaceae.
Externí odkaz:
https://doaj.org/article/697235b852314b92826d78126d05f020
Autor:
Steven P Gelone, Cathie Leister, James A. Dowell, Thomas Marbury, Wolfgang W Wicha, Jared L. Crandon, James Ermer
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 41:451-456
STUDY OBJECTIVE Lefamulin is a novel IV and oral pleuromutilin recently approved for the treatment of community-acquired bacterial pneumonia (CABP). Given that renal comorbidities are common in patients admitted for CABP, understanding the pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3143201f07458ad152214f2721385d41
https://doi.org/10.1002/phar.2523
https://doi.org/10.1002/phar.2523
Autor:
Thomas Marbury, Steven P Gelone, Cathie Leister, Wolfgang W Wicha, James Ermer, James A. Dowell, Jared L. Crandon
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 41:457-462
Study objective Lefamulin is a novel pleuromutilin recently approved by the FDA for the treatment of community-acquired bacterial pneumonia. Given that lefamulin is primarily metabolized by CYP450 Phase-1 reactions, this study evaluated the pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::904c17840281c89e0330d3da7008c0a4
https://doi.org/10.1002/phar.2522
https://doi.org/10.1002/phar.2522
Autor:
Monika T. Zmarlicka, Mitchell H. McClure, Jared L. Crandon, Sophia M. Cardwell, David P. Nicolau, Michael D Nailor
Publikováno v:
International Journal of Antimicrobial Agents. 47:451-456
A urinary tract infection (UTI) disease state management guideline, including risk-based antimicrobial recommendations, Foley catheter management and transitions of care, was implemented. This study evaluated the outcomes associated with implementati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66091309260439f6d38282f05a66811a
https://doi.org/10.1016/j.ijantimicag.2016.03.005
https://doi.org/10.1016/j.ijantimicag.2016.03.005
Autor:
Jared L. Crandon, Michael D Nailor, Sophia M. Cardwell, David P. Nicolau, Mitchell H. McClure
Publikováno v:
Hospital Practice. 44:33-40
Urinary tract infections (UTI) are among the most common bacterial diseases worldwide, with significant clinical and economic burden. Surveillance of pathogen epidemiology and risk factors for resistant pathogens in the hospital setting may improve t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::949d82dc06ddbfda19ea653e415c35a5
https://doi.org/10.1080/21548331.2016.1133214
https://doi.org/10.1080/21548331.2016.1133214
Autor:
Robert E. McLaughlin, Elise Gorseth, Michael T. Rooney, Ann E. Eakin, Aryun Kim, Asha S. Nayar, Andy S. Tsai, Kerry E. Murphy-Benenato, Alita A. Miller, Jared L. Crandon, David P. Nicolau, Christina M. Blinn, April Chen, David E. Ehmann, Amy Kutschke, Brian Dangel, Sara A. Patey
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:7743-7752
The objective of this study was to investigate the risk of attenuated efficacy due to adaptive resistance for the siderophore-conjugated monocarbam SMC-3176 in Pseudomonas aeruginosa by using a pharmacokinetic/pharmacodynamic (PK/PD) approach. MICs w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34771f5a04a33c3d3142e2a0d2b73c23
https://doi.org/10.1128/aac.00831-15
https://doi.org/10.1128/aac.00831-15
Autor:
David P. Nicolau, Jared L. Crandon
Publikováno v:
Pathogens, Vol 4, Iss 3, Pp 620-625 (2015)
Pathogens
Volume 4
Issue 3
Pages 620-625
Pathogens
Volume 4
Issue 3
Pages 620-625
We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum β-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a892b6206cb4389d5b7979870ef9e154
http://www.mdpi.com/2076-0817/4/3/620
http://www.mdpi.com/2076-0817/4/3/620
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:4956-4961
GSK2140944 is a novel bacterial type II topoisomerase inhibitor with in vitro activity against key causative respiratory pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). We described the pharmacodynamics of GSK2140944 against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9bde58a92479796276b84908630772
https://doi.org/10.1128/aac.00625-15
https://doi.org/10.1128/aac.00625-15
Autor:
Jared L. Crandon, David P. Nicolau
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:2688-2694
The combination of cefepime with AAI101, a novel extended-spectrum β-lactamase inhibitor, possesses potent in vitro activity against many resistant Gram-negative pathogens. Against a panel of 20 mostly carbapenemase-producing cefepime-nonsusceptible
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5c5477ea5959560a327df8872f8c8bf
https://doi.org/10.1128/aac.00033-15
https://doi.org/10.1128/aac.00033-15